ArticleDiabetes, obesity & metabolism2026
Glucose tolerance and mortality across 24 cancer types and stages: A K-CURE Nationwide registry study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
aimTo evaluate the association between baseline glycemic status and mortality among patients with cancer and to examine whether these associations differ by stage and cancer type. MATERIALS AND
methodsWe performed a nationwide cohort study using the Korean Cancer Public Library Database (K-CURE), which integrates national cancer registry, health screening, and cause-of-death records. A total of 671 366 adults newly diagnosed with one of 24 cancers between 2013 and 2019 were classified as normal glucose tolerance (NGT), impaired fasting glucose (IFG), or diabetes mellitus (DM). Multivariable Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for all-cause, cancer-specific, cardiovascular, and respiratory mortality. Analyses were stratified by Surveillance, Epidemiology, and End Results stage and cancer type, with sensitivity analyses applying 1-, 3-, and 5-year lag periods.
resultsOver a mean follow-up of 3.5 years, 171 104 deaths occurred. Compared with NGT, DM was associated with higher risks of all-cause (HR 1.34, 95% CI 1.32-1.35), cancer-specific (HR 1.31, 95% CI 1.30-1.33), cardiovascular (HR 1.46, 95% CI 1.35-1.58), and respiratory mortality (HR 1.43, 95% CI 1.30-1.56). IFG was associated with modestly increased risks of all-cause (HR 1.06, 95% CI 1.05-1.08) and cancer-specific mortality (HR 1.07, 95% CI 1.05-1.08). Stage-stratified analyses demonstrated the strongest associations in localised cancers with attenuation in advanced stages.
conclusionsDM and IFG were linked to poorer survival after cancer diagnosis, with the greatest impact in early-stage disease. These findings support integrating metabolic risk assessment and management into survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.